Its key medications—Remodulin, Tyvaso, and Orenitram—are sold to patients, hospitals, and specialty pharmacies. United Therapeutics Corporation (NASDAQ:UTHR) ended 2024 with record revenue and ...

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

The company's main products continue to be actively sold, and demand for them remains high: Tyvaso is showing +33% YoY, Orenitram and Remodulin are also growing, despite pressure from generics ...

Its key medications—Remodulin, Tyvaso, and Orenitram—are sold to patients, hospitals, and specialty pharmacies. United Therapeutics Corporation (NASDAQ:UTHR) ended 2024 with record revenue and ...

The increase in share-based compensation expense for the quarter ended December 31, 2024, as compared to the same period in 2023, was primarily due to: (1) an increase in stock option expense due ...

The growth in Remodulin revenues resulted from an increase in U.S. Remodulin revenues and, to a lesser extent, an increase in international Remodulin revenues, driven, in both cases, by an ...

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat ...

Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and ...